• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient.米拉贝隆治疗膀胱过度活动症：高龄患者的安全性和疗效。
Clin Interv Aging. 2020 Apr 23;15:575-581. doi: 10.2147/CIA.S174402. eCollection 2020.
2
Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine.米拉贝隆治疗储尿期下尿路症状/膀胱过度活动症的疗效和耐受性的系统评价与荟萃分析：与安慰剂和托特罗定的比较
Int J Urol. 2018 Mar;25(3):196-205. doi: 10.1111/iju.13498. Epub 2017 Dec 3.
3
The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.β3肾上腺素能受体激动剂米拉贝隆治疗老年患者膀胱过度活动症症状的疗效和耐受性。
Age Ageing. 2014 Sep;43(5):666-75. doi: 10.1093/ageing/afu017. Epub 2014 Mar 6.
4
Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.米拉贝隆治疗膀胱过度活动症：疗效、安全性和耐受性评价。
Neurourol Urodyn. 2014 Jan;33(1):17-30. doi: 10.1002/nau.22505. Epub 2013 Oct 11.
5
[MIRABEGRON--A NEW DRUG FOR TREATMENT OF OVERACTIVE BLADDER].米拉贝隆——一种治疗膀胱过度活动症的新药
Urologiia. 2015 Jul-Aug(4):121-4.
6
Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).米拉贝隆作为索利那新治疗膀胱过度活动症患者的“附加”疗法的安全性和有效性：日本的一项上市后开放标签研究（MILAI研究）。
BJU Int. 2015 Oct;116(4):612-22. doi: 10.1111/bju.13068. Epub 2015 Apr 23.
7
Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.β3肾上腺素能受体激动剂米拉贝隆在亚洲膀胱过度活动症患者中进行的一项随机、双盲、平行组、安慰剂和活性药物对照的多中心研究结果。
Neurourol Urodyn. 2015 Sep;34(7):685-92. doi: 10.1002/nau.22645. Epub 2014 Aug 17.
8
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).米拉贝隆与索利那新联合治疗膀胱过度活动症患者的疗效和安全性：一项随机、双盲、剂量范围、2 期研究（Symphony）的结果。
Eur Urol. 2015 Mar;67(3):577-88. doi: 10.1016/j.eururo.2014.02.012. Epub 2014 Feb 19.
9
Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.米拉贝隆治疗膀胱过度活动症：疗效、安全性及耐受性综述，重点关注男性、老年及抗毒蕈碱反应不佳人群以及亚洲膀胱过度活动症患者
Expert Rev Clin Pharmacol. 2017 Feb;10(2):131-151. doi: 10.1080/17512433.2017.1275570. Epub 2017 Jan 16.
10
Re: The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.回复：β3肾上腺素能受体激动剂米拉贝隆治疗老年患者膀胱过度活动症症状的疗效和耐受性
J Urol. 2015 Mar;193(3):947. doi: 10.1016/j.juro.2014.12.072. Epub 2014 Dec 18.

引用本文的文献

1
The Treatment Response and Safety Profile for Mirabegron in Women With Overactive Bladder and Hypertension.米拉贝隆治疗膀胱过度活动症合并高血压女性的疗效及安全性分析
Cureus. 2025 May 26;17(5):e84855. doi: 10.7759/cureus.84855. eCollection 2025 May.
2
Mirabegron 50 mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II/III, randomized, double-blind, parallel-design, placebo-controlled, multicenter, and multinational trials.米拉贝隆50毫克每日一次，长期治疗可使膀胱过度活动症的中年及老年患者获益最大化：一项对9项II/III期、随机、双盲、平行设计、安慰剂对照、多中心、跨国试验的系统评价和荟萃分析。
Front Surg. 2024 Aug 26;11:1372175. doi: 10.3389/fsurg.2024.1372175. eCollection 2024.
3
Posterior Tibial Nerve Stimulation With versus Without Mirabegron: A Randomized Controlled Trial.胫后神经刺激联合与不联合米拉贝隆治疗的随机对照试验。
Int Urogynecol J. 2024 Aug;35(8):1709-1717. doi: 10.1007/s00192-024-05835-y. Epub 2024 Aug 5.
4
Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder.米拉贝隆给药对膀胱过度活动症患者血压和脉搏率的影响。
Medicina (Kaunas). 2022 Jun 19;58(6):825. doi: 10.3390/medicina58060825.
5
A non-interventional cross-sectional re-contact study investigating the relationship between overactive bladder and frailty in older adults in Japan.一项在日本进行的非介入性、横断面再联系研究，旨在调查老年人群中膀胱过度活动症与虚弱之间的关系。
BMC Geriatr. 2022 Jan 21;22(1):68. doi: 10.1186/s12877-022-02756-7.
6
Managing Nocturia in Frail Older Adults.衰弱老年人夜尿症的管理。
Drugs Aging. 2021 Feb;38(2):95-109. doi: 10.1007/s40266-020-00815-5. Epub 2020 Nov 24.

本文引用的文献

1
Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).米拉贝隆治疗≥65 岁伴膀胱过度活动症的有效性、安全性和耐受性：一项四期、双盲、随机、安慰剂对照研究（PILLAR）。
Eur Urol. 2020 Feb;77(2):211-220. doi: 10.1016/j.eururo.2019.10.002. Epub 2019 Nov 13.
2
Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.米拉贝隆的安全性和疗效：接受米拉贝隆、抗毒蕈碱药物或安慰剂的膀胱过度活动症患者大型综合临床试验数据库分析。
Eur Urol. 2020 Jan;77(1):119-128. doi: 10.1016/j.eururo.2019.09.024. Epub 2019 Oct 18.
3
Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex.多准则决策分析在治疗膀胱过度活动症症状复杂药物治疗中的应用
Eur Urol Focus. 2020 May 15;6(3):522-530. doi: 10.1016/j.euf.2019.09.020. Epub 2019 Oct 15.
4
Vibegron: First Global Approval.维贝格隆：首个全球批准。
Drugs. 2018 Nov;78(17):1835-1839. doi: 10.1007/s40265-018-1006-3.
5
Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).米拉贝隆与索利那新联合治疗与单药治疗对膀胱过度活动症患者的长期安全性和疗效比较：一项随机、多中心 3 期研究（SYNERGY II）。
Eur Urol. 2018 Oct;74(4):501-509. doi: 10.1016/j.eururo.2018.05.005. Epub 2018 Jun 1.
6
Vibegron, a Novel Potent and Selective β-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study.Vibegron，一种新型高效且选择性 β-肾上腺素受体激动剂，用于治疗膀胱过度活动症患者：一项随机、双盲、安慰剂对照的 3 期研究。
Eur Urol. 2018 May;73(5):783-790. doi: 10.1016/j.eururo.2017.12.022. Epub 2018 Feb 1.
7
Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.米拉贝隆与索利那新联合治疗老年患者膀胱过度活动症：来自 BESIDE 研究的预先指定分析。
Eur Urol Focus. 2017 Dec;3(6):629-638. doi: 10.1016/j.euf.2017.08.008. Epub 2017 Sep 12.
8
CUA guideline on adult overactive bladder.加拿大泌尿外科学会成人膀胱过度活动症指南
Can Urol Assoc J. 2017 May;11(5):E142-E173. doi: 10.5489/cuaj.4586. Epub 2017 May 9.
9
The association between lower urinary tract symptoms and falls: Forming a theoretical model for a research agenda.下尿路症状与跌倒之间的关联：构建研究议程的理论模型。
Neurourol Urodyn. 2018 Jan;37(1):501-509. doi: 10.1002/nau.23295. Epub 2017 May 4.
10
Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).米拉贝隆与索利那新联合用药对比单药治疗及安慰剂治疗对膀胱过度活动症患者的疗效和安全性（协同研究）
BJU Int. 2017 Oct;120(4):562-575. doi: 10.1111/bju.13882. Epub 2017 Jun 8.

米拉贝隆治疗膀胱过度活动症：高龄患者的安全性和疗效。

Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient.

机构信息

University of Alberta, Division of Geriatric Medicine, Edmonton, Alberta, Canada.

Great Western Hospitals NHS Foundation Trust, Swindon SN3 6BB, UK.

出版信息

Clin Interv Aging. 2020 Apr 23;15:575-581. doi: 10.2147/CIA.S174402. eCollection 2020.

DOI:10.2147/CIA.S174402
PMID:32368024
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7185319/
Abstract

Lower urinary tract symptoms, including urgency, urgency incontinence, frequency, and nocturia, are highly prevalent in older adults and are associated with significant morbidity and impairment in quality of life. When conservative measures such as bladder training fail to improve symptoms, pharmacological management is recommended by national and international guidelines. Mirabegron, an agonist of the β3 adrenergic receptor, demonstrates similar efficacy to the anticholinergic drugs without the risk of anticholinergic effects, but experience and evidence in the very elderly population are limited. This narrative review examines the current evidence base for mirabegron in very elderly adults.

摘要

下尿路症状，包括尿急、急迫性尿失禁、尿频和夜尿，在老年人中非常普遍，并与显著的发病率和生活质量受损相关。当保守措施，如膀胱训练未能改善症状时，国家和国际指南建议进行药物治疗。米拉贝隆是一种β3 肾上腺素能受体激动剂，其疗效与抗胆碱能药物相似，而没有抗胆碱能作用的风险，但在非常老年人群中的经验和证据有限。本综述探讨了米拉贝隆在非常老年人群中的现有证据基础。